Expression hierarchy of T cell epitopes from melanoma differentiation antigens: Unexpected high level presentation of tyrosinase-HLA-A2 complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies

Journal of Immunology

Volumn 182, Issue 10, 2009, Pages 6328-6341

  Michaeli, Yael ^a   Denkberg, Galit ^b   Sinik, Keren ^a   Lantzy, Liz ^c   Chih Sheng, Chiang ^c   Beauverd, Celine ^d   Ziv, Tamar ^a   Romero, Pedro ^d   Reiter, Yoram ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Applied Immune Technologies Ltd   (Israel)

^c MannKind Corporation   (United States)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DIFFERENTIATION ANTIGEN; EPITOPE; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; MELAN A; MELANOMA ANTIGEN; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; PEPTIDE; RECOMBINANT ANTIBODY;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; T LYMPHOCYTE;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GP100 MELANOMA ANTIGEN; HLA-A2 ANTIGEN; HUMANS; MART-1 ANTIGEN; MELANOMA; MEMBRANE GLYCOPROTEINS; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77952377602     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0801898     Document Type: Article

References (41)

1. Morin, P. J., A. B. Sparks, V. Korinek, N. Barker, H. Clevers, B. Vogelstein, and K. W. Kinzler. 1997. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275: 1787-1790.
2. Nakada, T., Y. Noguchi, S. Satoh, T. Ono, T. Saika, T. Kurashige, S. Gnjatic, G. Ritter, Y. T. Chen, E. Stockert, et al. 2003. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun. 3: 10-21. (Pubitemid 38813905)
3. Lee, L., R. F. Wang, X. Wang, A. Mixon, B. E. Johnson, S. A. Rosenberg, and D. S. Schrump. 1999. NY-ESO-1 may be a potential target for lung cancer immunotherapy. Cancer J. Sci. Am. 5: 20-25. (Pubitemid 29108642)
4. de Vries, T. J., A. Fourkour, T. Wobbes, G. Verkroost, D. J. Ruiter, and G. N. van Muijen. 1997. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 57: 3223-3229.
5. 280-288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. 7: 3012-3024.
6. Tanaka, S., M. Harada, T. Mine, M. Noguchi, R. Gohara, K. Azuma, M. Tamura, A. Yamada, A. Morinaga, M. Nishikori, et al. 2003. Peptide vaccination for patients with melanoma and other types of cancer based on preexisting peptidespecific cytotoxic T-lymphocyte precursors in the periphery. J. Immunother. 26: 357-366. (Pubitemid 36858720)
7. Schwartz, R. H. 2003. T cell anergy. Annu. Rev. Immunol. 21: 305-334.
8. Yang, L., and D. P. Carbone. 2004. Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res. 92: 13-27. (Pubitemid 39458111)
9. Zhou, G., Z. Lu, J. D. McCadden, H. I. Levitsky, and A. L. Marson. 2004. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J. Exp. Med. 200: 1581-1592. (Pubitemid 40094182)
10. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176: 1582-1587.
11. Wolf, A. M., D. Wolf, M. Steurer, G. Gastl, E. Gunsilius, and B. Grubeck-Loebenstein. 2003. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9: 606-612. (Pubitemid 36182591)
12. Machiels, J. P., B. N. van, and M. Marchand. 2002. Peptide-based cancer vaccines. Semin. Oncol. 29: 494-502.
13. Belli, F., A. Testori, L. Rivoltini, M. Maio, G. Andreola, M. R. Sertoli, G. Gallino, A. Piris, A. Cattelan, I. Lazzari, et al. 2002. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20: 4169-4180. (Pubitemid 35191019)
14. Lee, K. H., E. Wang, M. B. Nielsen, J. Wunderlich, S. Migueles, M. Connors, S. M. Steinberg, S. A. Rosenberg, and F. M. Marincola. 1999. Increased vaccinespecific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163: 6292-6300.
15. Leen, A. M., C. M. Rooney, and A. E. Foster. 2007. Improving T cell therapy for cancer. Annu. Rev. Immunol. 25: 243-265.
16. Valmori, D., M. J. Pittet, C. Vonarbourg, D. Rimoldi, D. Lienard, D. Speiser, R. Dunbar, V. Cerundolo, J. C. Cerottini, and P. Romero. 1999. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLAA* 0201-associated tyrosinase peptide 368-376. Cancer Res. 59: 4050-4055. (Pubitemid 29393576)
17. Romero, P., P. R. Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J. L. Chen, D. Lienard, J. C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188: 1641-1650. (Pubitemid 28516109)
18. Maczek, C., T. G. Berger, B. Schuler-Thurner, E. S. Schultz, A. Hamann, P. R. Dunbar, V. Cerundolo, A. Steinkasserer, and G. Schuler. 2005. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase-and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients. Int. J. Cancer. 115: 450-455. (Pubitemid 40663750)
19. Porgador, A., J. W. Yewdell, Y. Deng, J. R. Bennink, and R. N. Germain. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6: 715-726. (Pubitemid 27305734)
20. Denkberg, G., C. J. Cohen, D. Segal, A. F. Kirkin, and Y. Reiter. 2000. Recombinant human single-chain MHC-peptide complexes made from E. coli by in vitro refolding: functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens. Eur. J. Immunol. 30: 3522-3532. (Pubitemid 32005224)
21. Cohen, C. J., G. Denkberg, A. Lev, M. Epel, and Y. Reiter. 2003. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. J. Mol. Recognit. 16: 324-332.
22. Cohen, C. J., N. Hoffmann, M. Farago, H. R. Hoogenboom, L. Eisenbach, and Y. Reiter. 2002. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res. 62: 5835-5844.
23. Denkberg, G., C. J. Cohen, A. Lev, P. Chames, H. R. Hoogenboom, and Y. Reiter. 2002. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proc. Natl. Acad. Sci. USA 99: 9421-9426. (Pubitemid 34764629)
24. Cohen, C. J., O. Sarig, Y. Yamano, U. Tomaru, S. Jacobson, and Y. Reiter. 2003. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptidespecific, MHC-restricted human recombinant antibodies. J. Immunol. 170: 4349-4361.
25. Halaban, R., E. Cheng, S. Svedine, R. Aron, and D. N. Hebert. 2001. Proper folding and endoplasmic reticulum to Golgi transport of tyrosinase are induced by its substrates, DOPA and tyrosine. J. Biol. Chem. 276: 11933-11938. (Pubitemid 37385352)
26. Storkus, W. J., H. J. Zeh, III, R. D. Salter, and M. T. Lotze. 1993. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J. Immunother. 14: 94-103.
27. Denkberg, G., C. J. Cohen, A. Lev, P. Chames, H. R. Hoogenboom, and Y. Reiter. 2002. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proc. Natl. Acad. Sci. USA 99: 9421-9426. (Pubitemid 34764629)
28. Reinke, S., P. Koniger, G. Herberth, H. Audring, H. Wang, J. Ma, Y. Guo, W. Sterry, and U. Trefzer. 2005. Differential expression of MART-1, tyrosinase, and SM5-1 in primary and metastatic melanoma. Am. J. Dermatopathol. 27: 401-406. (Pubitemid 41383293)
29. Takeuchi, H., C. Kuo, D. L. Morton, H. J. Wang, and D. S. Hoon. 2003. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res. 63: 441-448. (Pubitemid 36152505)
30. Brichard, V., A. Van Pel, T. Wolfel, C. Wolfel, E. De Plaen, B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178: 489-495. (Pubitemid 23218197)
31. Skipper, J. C., R. C. Hendrickson, P. H. Gulden, V. Brichard, P. A. Van, Y. Chen, J. Shabanowitz, T. Wolfel, C. L. Slingluff, Jr., T. Boon, et al. 1996. An HLAA2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183: 527-534.
32. Jimbow, K., J. S. Park, F. Kato, K. Hirosaki, K. Toyofuku, C. Hua, and T. Yamashita. 2000. Assembly, target-signaling and intracellular transport of tyrosinase gene family proteins in the initial stage of melanosome biogenesis. Pigm. Cell Res. 13: 222-229. (Pubitemid 30610798)
33. Engelhard, V. H., A. G. Brickner, and A. L. Zarling. 2002. Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire. Mol. Immunol. 39: 127-137.
34. Halaban, R., R. S. Patton, E. Cheng, S. Svedine, E. S. Trombetta, M. L. Wahl, S. Ariyan, and D. N. Hebert. 2002. Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathway. J. Biol. Chem. 277: 14821-14828. (Pubitemid 34952554)
35. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180: 347-352. (Pubitemid 24181083)
36. Kawakami, Y., N. Dang, X. Wang, J. Tupesis, P. F. Robbins, R. F. Wang, J. R. Wunderlich, J. R. Yannelli, and S. A. Rosenberg. 2000. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J. Immunother. 23: 17-27. (Pubitemid 30079822)
37. Romero, P., D. Valmori, M. J. Pittet, A. Zippelius, D. Rimoldi, F. Levy, V. Dutoit, M. Ayyoub, V. Rubio-Godoy, O. Michielin, et al. 2002. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol. Rev. 188: 81-96. (Pubitemid 35398867)
38. Rocha, B., A. Grandien, and A. A. Freitas. 1995. Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance. J. Exp. Med. 181: 993-1003.
39. Taams, L. S., E. W. van, and M. H. Wauben. 1999. Dose-dependent induction of distinct anergic phenotypes: multiple levels of T cell anergy. J. Immunol. 162: 1974-1981.
40. Oved, K., O. Ziv, J. Jacob-Hirsch, R. Noy, H. Novak, O. Makler, D. Galit, S. Keren, D. Segal, C. Gefen-Dor, et al. 2007. A novel postpriming regulatory check point of effector/memory T cells dictated through antigen density threshold-dependent anergy. J. Immunol. 178: 2307-2317. (Pubitemid 46233429)
41. Reiter, Y., C. A. Di, L. Fugger, J. Engberg, and I. Pastan. 1997. Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity. Proc. Natl. Acad. Sci. USA 94: 4631-4636. (Pubitemid 27194294)